Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009)

Yu Tao Xiang, Julie Kreyenbuhl, Faith B. Dickerson, Gabor S. Ungvari, Chuan Yue Wang, Tian Mei Si, Edwin H. Lee, Yan Ling He, Helen F. Chiu, Shu Yu Yang, Mian Yoon Chong, Chay Hoon Tan, Ee Heok Kua, Senta Fujii, Kang Sim, Michael K. Yong, Jitendra K. Trivedi, Eun Kee Chung, Pichet Udomratn, Kok Yoon CheeNorman Sartorius, Naotaka Shinfuku

Research output: Contribution to journalArticle

Abstract

Objective: This study examined the prescribing patterns of several first- (FGAs) and second generation antipsychotic (SGAs) medications administered to older Asian patients with schizophrenia during the period between 2001 and 2009. Method: Information on hospitalized patients with schizophrenia aged 65 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (20012009). There were no older patients in Thailand, therefore data on 467 patients in eight Asian countries and territories including China, Hong Kong SAR, India, Japan, Korea, Malaysia, Singapore, and Taiwan were analysed. Cross-sectional socio-demographic data, clinical characteristics and antipsychotic prescriptions were assessed using a standardized protocol and data collection procedure. Results: Of the 467 patients, 192 patients (41.1%) received FGAs only, 166 (35.5%) received SGAs only and 109 (23.3%) received a combination of FGAs and SGAs. Of the FGAs, haloperidol was the most commonly used (31.3%; mean 9.4 ± 6.7 mg/day), followed by chlorpromazine (15.4%; mean 126.4 ± 156.4 mg/day) and sulpiride (6.6%; mean 375.0 ± 287.0 mg/day). Of the SGAs, risperidone was the most commonly used (31.5%; mean 4.5 ± 2.7 mg/day), followed by olanzapine (13.1%; mean 13.6 ± 6.5 mg/day), quetiapine (7.3%; mean 325.0 ± 237.3 mg/day) and aripiprazole (1.9%; mean 17.6 ± 7.7 mg/day). Conclusions: FGAs and higher doses of certain SGAs (risperidone, olanzapine and quetiapine) were still commonly dispensed to older Asian patients with schizophrenia. Considering older patients reduced tolerability of potentially severe side effects associated with FGAs and higher doses of certain SGAs, continuing education and training addressing the rational use of antipsychotics in this population is clearly needed.

Original languageEnglish (US)
Pages (from-to)1159-1164
Number of pages6
JournalAustralian and New Zealand Journal of Psychiatry
Volume46
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Antipsychotic Agents
Schizophrenia
olanzapine
Risperidone
Prescriptions
Sulpiride
Malaysia
Singapore
Continuing Education
Chlorpromazine
Hong Kong
Haloperidol
Thailand
Korea
Taiwan
India
China
Japan
Demography
Databases

Keywords

  • Asia
  • older patients
  • prescription patterns
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009). / Xiang, Yu Tao; Kreyenbuhl, Julie; Dickerson, Faith B.; Ungvari, Gabor S.; Wang, Chuan Yue; Si, Tian Mei; Lee, Edwin H.; He, Yan Ling; Chiu, Helen F.; Yang, Shu Yu; Chong, Mian Yoon; Tan, Chay Hoon; Kua, Ee Heok; Fujii, Senta; Sim, Kang; Yong, Michael K.; Trivedi, Jitendra K.; Chung, Eun Kee; Udomratn, Pichet; Chee, Kok Yoon; Sartorius, Norman; Shinfuku, Naotaka.

In: Australian and New Zealand Journal of Psychiatry, Vol. 46, No. 12, 12.2012, p. 1159-1164.

Research output: Contribution to journalArticle

Xiang, YT, Kreyenbuhl, J, Dickerson, FB, Ungvari, GS, Wang, CY, Si, TM, Lee, EH, He, YL, Chiu, HF, Yang, SY, Chong, MY, Tan, CH, Kua, EH, Fujii, S, Sim, K, Yong, MK, Trivedi, JK, Chung, EK, Udomratn, P, Chee, KY, Sartorius, N & Shinfuku, N 2012, 'Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009)', Australian and New Zealand Journal of Psychiatry, vol. 46, no. 12, pp. 1159-1164. https://doi.org/10.1177/0004867412453625
Xiang, Yu Tao ; Kreyenbuhl, Julie ; Dickerson, Faith B. ; Ungvari, Gabor S. ; Wang, Chuan Yue ; Si, Tian Mei ; Lee, Edwin H. ; He, Yan Ling ; Chiu, Helen F. ; Yang, Shu Yu ; Chong, Mian Yoon ; Tan, Chay Hoon ; Kua, Ee Heok ; Fujii, Senta ; Sim, Kang ; Yong, Michael K. ; Trivedi, Jitendra K. ; Chung, Eun Kee ; Udomratn, Pichet ; Chee, Kok Yoon ; Sartorius, Norman ; Shinfuku, Naotaka. / Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009). In: Australian and New Zealand Journal of Psychiatry. 2012 ; Vol. 46, No. 12. pp. 1159-1164.
@article{55cc01e1750d49c3b0db5cef73d4c435,
title = "Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009)",
abstract = "Objective: This study examined the prescribing patterns of several first- (FGAs) and second generation antipsychotic (SGAs) medications administered to older Asian patients with schizophrenia during the period between 2001 and 2009. Method: Information on hospitalized patients with schizophrenia aged 65 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (20012009). There were no older patients in Thailand, therefore data on 467 patients in eight Asian countries and territories including China, Hong Kong SAR, India, Japan, Korea, Malaysia, Singapore, and Taiwan were analysed. Cross-sectional socio-demographic data, clinical characteristics and antipsychotic prescriptions were assessed using a standardized protocol and data collection procedure. Results: Of the 467 patients, 192 patients (41.1{\%}) received FGAs only, 166 (35.5{\%}) received SGAs only and 109 (23.3{\%}) received a combination of FGAs and SGAs. Of the FGAs, haloperidol was the most commonly used (31.3{\%}; mean 9.4 ± 6.7 mg/day), followed by chlorpromazine (15.4{\%}; mean 126.4 ± 156.4 mg/day) and sulpiride (6.6{\%}; mean 375.0 ± 287.0 mg/day). Of the SGAs, risperidone was the most commonly used (31.5{\%}; mean 4.5 ± 2.7 mg/day), followed by olanzapine (13.1{\%}; mean 13.6 ± 6.5 mg/day), quetiapine (7.3{\%}; mean 325.0 ± 237.3 mg/day) and aripiprazole (1.9{\%}; mean 17.6 ± 7.7 mg/day). Conclusions: FGAs and higher doses of certain SGAs (risperidone, olanzapine and quetiapine) were still commonly dispensed to older Asian patients with schizophrenia. Considering older patients reduced tolerability of potentially severe side effects associated with FGAs and higher doses of certain SGAs, continuing education and training addressing the rational use of antipsychotics in this population is clearly needed.",
keywords = "Asia, older patients, prescription patterns, schizophrenia",
author = "Xiang, {Yu Tao} and Julie Kreyenbuhl and Dickerson, {Faith B.} and Ungvari, {Gabor S.} and Wang, {Chuan Yue} and Si, {Tian Mei} and Lee, {Edwin H.} and He, {Yan Ling} and Chiu, {Helen F.} and Yang, {Shu Yu} and Chong, {Mian Yoon} and Tan, {Chay Hoon} and Kua, {Ee Heok} and Senta Fujii and Kang Sim and Yong, {Michael K.} and Trivedi, {Jitendra K.} and Chung, {Eun Kee} and Pichet Udomratn and Chee, {Kok Yoon} and Norman Sartorius and Naotaka Shinfuku",
year = "2012",
month = "12",
doi = "10.1177/0004867412453625",
language = "English (US)",
volume = "46",
pages = "1159--1164",
journal = "Australian and New Zealand Journal of Psychiatry",
issn = "0004-8674",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001-2009)

AU - Xiang, Yu Tao

AU - Kreyenbuhl, Julie

AU - Dickerson, Faith B.

AU - Ungvari, Gabor S.

AU - Wang, Chuan Yue

AU - Si, Tian Mei

AU - Lee, Edwin H.

AU - He, Yan Ling

AU - Chiu, Helen F.

AU - Yang, Shu Yu

AU - Chong, Mian Yoon

AU - Tan, Chay Hoon

AU - Kua, Ee Heok

AU - Fujii, Senta

AU - Sim, Kang

AU - Yong, Michael K.

AU - Trivedi, Jitendra K.

AU - Chung, Eun Kee

AU - Udomratn, Pichet

AU - Chee, Kok Yoon

AU - Sartorius, Norman

AU - Shinfuku, Naotaka

PY - 2012/12

Y1 - 2012/12

N2 - Objective: This study examined the prescribing patterns of several first- (FGAs) and second generation antipsychotic (SGAs) medications administered to older Asian patients with schizophrenia during the period between 2001 and 2009. Method: Information on hospitalized patients with schizophrenia aged 65 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (20012009). There were no older patients in Thailand, therefore data on 467 patients in eight Asian countries and territories including China, Hong Kong SAR, India, Japan, Korea, Malaysia, Singapore, and Taiwan were analysed. Cross-sectional socio-demographic data, clinical characteristics and antipsychotic prescriptions were assessed using a standardized protocol and data collection procedure. Results: Of the 467 patients, 192 patients (41.1%) received FGAs only, 166 (35.5%) received SGAs only and 109 (23.3%) received a combination of FGAs and SGAs. Of the FGAs, haloperidol was the most commonly used (31.3%; mean 9.4 ± 6.7 mg/day), followed by chlorpromazine (15.4%; mean 126.4 ± 156.4 mg/day) and sulpiride (6.6%; mean 375.0 ± 287.0 mg/day). Of the SGAs, risperidone was the most commonly used (31.5%; mean 4.5 ± 2.7 mg/day), followed by olanzapine (13.1%; mean 13.6 ± 6.5 mg/day), quetiapine (7.3%; mean 325.0 ± 237.3 mg/day) and aripiprazole (1.9%; mean 17.6 ± 7.7 mg/day). Conclusions: FGAs and higher doses of certain SGAs (risperidone, olanzapine and quetiapine) were still commonly dispensed to older Asian patients with schizophrenia. Considering older patients reduced tolerability of potentially severe side effects associated with FGAs and higher doses of certain SGAs, continuing education and training addressing the rational use of antipsychotics in this population is clearly needed.

AB - Objective: This study examined the prescribing patterns of several first- (FGAs) and second generation antipsychotic (SGAs) medications administered to older Asian patients with schizophrenia during the period between 2001 and 2009. Method: Information on hospitalized patients with schizophrenia aged 65 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (20012009). There were no older patients in Thailand, therefore data on 467 patients in eight Asian countries and territories including China, Hong Kong SAR, India, Japan, Korea, Malaysia, Singapore, and Taiwan were analysed. Cross-sectional socio-demographic data, clinical characteristics and antipsychotic prescriptions were assessed using a standardized protocol and data collection procedure. Results: Of the 467 patients, 192 patients (41.1%) received FGAs only, 166 (35.5%) received SGAs only and 109 (23.3%) received a combination of FGAs and SGAs. Of the FGAs, haloperidol was the most commonly used (31.3%; mean 9.4 ± 6.7 mg/day), followed by chlorpromazine (15.4%; mean 126.4 ± 156.4 mg/day) and sulpiride (6.6%; mean 375.0 ± 287.0 mg/day). Of the SGAs, risperidone was the most commonly used (31.5%; mean 4.5 ± 2.7 mg/day), followed by olanzapine (13.1%; mean 13.6 ± 6.5 mg/day), quetiapine (7.3%; mean 325.0 ± 237.3 mg/day) and aripiprazole (1.9%; mean 17.6 ± 7.7 mg/day). Conclusions: FGAs and higher doses of certain SGAs (risperidone, olanzapine and quetiapine) were still commonly dispensed to older Asian patients with schizophrenia. Considering older patients reduced tolerability of potentially severe side effects associated with FGAs and higher doses of certain SGAs, continuing education and training addressing the rational use of antipsychotics in this population is clearly needed.

KW - Asia

KW - older patients

KW - prescription patterns

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84873646896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873646896&partnerID=8YFLogxK

U2 - 10.1177/0004867412453625

DO - 10.1177/0004867412453625

M3 - Article

C2 - 22790175

AN - SCOPUS:84873646896

VL - 46

SP - 1159

EP - 1164

JO - Australian and New Zealand Journal of Psychiatry

JF - Australian and New Zealand Journal of Psychiatry

SN - 0004-8674

IS - 12

ER -